rivaroxaban News
Most Popular rivaroxaban Story
FDA review drops a bombshell on Bayer, J&J anti-clotting drug Xarelto
The FDA dropped a bombshell on the anti-clotting drug Xarelto (rivaroxaban) this morning, noting in an agency review that Bayer ($BAYN) and Johnson & Johnson ($JNJ) had offered insufficient data Read more...
Latest Headlines
- September 9, 2011
- November 19, 2009
- May 28, 2009
- March 20, 2009
- November 10, 2008
- July 25, 2008
- May 30, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
